Clifford Swan Investment Counsel’s Teva Pharmaceuticals TEVA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-10,100
| Closed | -$93K | – | 342 |
|
|
2021
Q3 | $93K | Hold |
10,100
| – | – | ﹤0.01% | 328 |
|
|
2021
Q2 | $101K | Hold |
10,100
| – | – | ﹤0.01% | 321 |
|
|
2021
Q1 | $117K | Hold |
10,100
| – | – | ﹤0.01% | 322 |
|
|
2020
Q4 | $97K | Sell |
10,100
-2,900
| -22% | -$27.8K | ﹤0.01% | 318 |
|
|
2020
Q3 | $117K | Sell |
13,000
-500
| -4% | -$5.29K | 0.01% | 310 |
|
|
2020
Q2 | $166K | Buy |
13,500
+500
| +4% | +$5.66K | 0.01% | 296 |
|
|
2020
Q1 | $117K | Hold |
13,000
| – | – | 0.01% | 288 |
|
|
2019
Q4 | $127K | Sell |
13,000
-1,820
| -12% | -$16.2K | 0.01% | 314 |
|
|
2019
Q3 | $102K | Sell |
14,820
-105,863
| -88% | -$811K | 0.01% | 309 |
|
|
2019
Q2 | $1.11M | Buy |
120,683
+370
| +0.3% | +$4.46K | 0.06% | 158 |
|
|
2019
Q1 | $1.89M | Sell |
120,313
-7,385
| -6% | -$130K | 0.1% | 130 |
|
|
2018
Q4 | $1.97M | Sell |
127,698
-4,600
| -3% | -$94.3K | 0.12% | 121 |
|
|
2018
Q3 | $2.85M | Sell |
132,298
-736
| -0.6% | -$17.1K | 0.15% | 115 |
|
|
2018
Q2 | $3.23M | Sell |
133,034
-3,870
| -3% | -$78.9K | 0.18% | 109 |
|
|
2018
Q1 | $2.34M | Sell |
136,904
-19,610
| -13% | -$383K | 0.13% | 115 |
|
|
2017
Q4 | $2.97M | Sell |
156,514
-64,780
| -29% | -$974K | 0.16% | 112 |
|
|
2017
Q3 | $3.9M | Sell |
221,294
-8,060
| -4% | -$181K | 0.24% | 101 |
|
|
2017
Q2 | $7.62M | Buy |
229,354
+56,925
| +33% | +$1.76M | 0.48% | 70 |
|
|
2017
Q1 | $5.53M | Buy |
172,429
+59,575
| +53% | +$2.03M | 0.35% | 83 |
|
|
2016
Q4 | $4.09M | Buy |
112,854
+57,545
| +104% | +$2.3M | 0.27% | 91 |
|
|
2016
Q3 | $2.54M | Sell |
55,309
-900
| -2% | -$47K | 0.17% | 108 |
|
|
2016
Q2 | $2.82M | Buy |
56,209
+22,200
| +65% | +$1.18M | 0.2% | 103 |
|
|
2016
Q1 | $1.82M | Buy |
34,009
+500
| +1% | +$29.3K | 0.12% | 121 |
|
|
2015
Q4 | $2.2M | Buy |
33,509
+50
| +0.1% | +$3.09K | 0.15% | 110 |
|
|
2015
Q3 | $1.89M | Sell |
33,459
-10,415
| -24% | -$675K | 0.14% | 111 |
|
|
2015
Q2 | $2.59M | Sell |
43,874
-18,100
| -29% | -$1.12M | 0.17% | 104 |
|
|
2015
Q1 | $3.86M | Hold |
61,974
| – | – | 0.25% | 86 |
|
|
2014
Q4 | $3.56M | Sell |
61,974
-14,100
| -19% | -$786K | 0.24% | 89 |
|
|
2014
Q3 | $4.09M | Sell |
76,074
-18,182
| -19% | -$963K | 0.28% | 81 |
|
|
2014
Q2 | $4.94M | Sell |
94,256
-30,479
| -24% | -$1.56M | 0.33% | 76 |
|
|
2014
Q1 | $6.59M | Sell |
124,735
-30,017
| -19% | -$1.39M | 0.46% | 62 |
|
|
2013
Q4 | $6.2M | Sell |
154,752
-3,477
| -2% | -$137K | 0.45% | 63 |
|
|
2013
Q3 | $5.98M | Buy |
158,229
+7,167
| +5% | +$280K | 0.48% | 64 |
|
|
2013
Q2 | $5.92M | Buy |
+151,062
| New | +$5.88M | 0.49% | 61 |
|
Other funds holding TEVA
ACM
MMH
MIFH
CI
PF
LIM
Clifford Swan Investment Counsel's TEVA Position: Q4 2021 in Review
Clifford Swan Investment Counsel sold out of Teva Pharmaceuticals (TEVA) in Q4 2021, closing a stake of 10,100 shares — an estimated $93K sold.
Clifford Swan Investment Counsel first reported a position in TEVA in Q2 2013 and held it in 34 quarters. The position peaked at $7.62M in Q2 2017. 450 funds tracked by Wall St. Rank hold TEVA as of Q4 2021.
- Clifford Swan Investment Counsel reported no remaining Teva Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
- Clifford Swan Investment Counsel sold 10,100 Teva Pharmaceuticals shares in Q4 2021, an estimated $93K.
- Clifford Swan Investment Counsel first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 34 quarters.
- Clifford Swan Investment Counsel's Teva Pharmaceuticals position peaked at $7.62M in Q2 2017.
- 450 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2021.
Based on Clifford Swan Investment Counsel's 13F filing for Q4 2021, filed 11 Feb 2022.